Global GPCR-targeting Drug Supply, Demand and Key Producers, 2023-2029

Global GPCR-targeting Drug Supply, Demand and Key Producers, 2023-2029

The global GPCR-targeting Drug market size is expected to reach $ 491.3 million by 2029, rising at a market growth of 2.5% CAGR during the forecast period (2023-2029).

GPCRs or G protein-coupled receptors are proteins located on the cell surface that recognize extracellular substances and transmit signals across the cell membrane. GPCRs do this by activating guanine nucleotide-binding proteins (G protein) that are responsible for signal transduction inside the cell. The signal delivery is very important in various cellular responses including cell growth, gene transcription, post-translational changes, and communication with other cells. This brings on adjustments in the body to adapt to the environmental changes such as increased heart rate when feeling threatened or change in vision in response to dim light.

This report studies the global GPCR-targeting Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for GPCR-targeting Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of GPCR-targeting Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global GPCR-targeting Drug total market, 2018-2029, (USD Million)

Global GPCR-targeting Drug total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: GPCR-targeting Drug total market, key domestic companies and share, (USD Million)

Global GPCR-targeting Drug revenue by player and market share 2018-2023, (USD Million)

Global GPCR-targeting Drug total market by Type, CAGR, 2018-2029, (USD Million)

Global GPCR-targeting Drug total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global GPCR-targeting Drug market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include PerkinElmer, Thermo Fisher Scientific, Merck, BD Biosciences, Molecular Devices, Promega, Qiagen, Abcam and Corning, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World GPCR-targeting Drug market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global GPCR-targeting Drug Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global GPCR-targeting Drug Market, Segmentation by Type
Reagent Test Kit
Substrate

Global GPCR-targeting Drug Market, Segmentation by Application
Oncology
Cardiovascular
Central Nervous
Other

Companies Profiled:
PerkinElmer
Thermo Fisher Scientific
Merck
BD Biosciences
Molecular Devices
Promega
Qiagen
Abcam
Corning
Discoverx
Cisbio

Key Questions Answered

1. How big is the global GPCR-targeting Drug market?

2. What is the demand of the global GPCR-targeting Drug market?

3. What is the year over year growth of the global GPCR-targeting Drug market?

4. What is the total value of the global GPCR-targeting Drug market?

5. Who are the major players in the global GPCR-targeting Drug market?

6. What are the growth factors driving the market demand?